Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAT | P00750 | 1/20 | 0.43 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 2/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALPL | P05186 | 1/20 | 0.38 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.38 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1923712 | 0.93 | DPP4 (0.39) | PLATGPBAR1DPP4DPP8DPP9 | |
| SCHEMBL2255169 | 0.91 | DPP4 (0.47) | DPP4DPP8DPP9CNR1CNR2 | |
| SCHEMBL1923132 | 0.90 | LPAR1 (0.36) | PLATDPP4DPP8DPP9CNR1 | |
| SCHEMBL1922542 | 0.86 | CRHR1 (0.45) | DPP4DPP8DPP9CNR1CNR2 | |
| SCHEMBL1922628 | 0.83 | DPP4 (0.42) | PLATDPP4DPP8DPP9CNR1 | |
| SCHEMBL1922615 | 0.82 | GPBAR1 (0.47) | GPBAR1DPP4DPP8TSHRCRHR1 | |
| SCHEMBL1922297 | 0.80 | LMNA (0.48) | DPP4DPP8KMT2ACRHR1NPC1 | |
| SCHEMBL1922617 | 0.80 | TSHR (0.48) | DPP4DPP8DPP9CNR1CNR2 | |
| SCHEMBL1922248 | 0.79 | GPBAR1 (0.45) | GPBAR1DPP4DPP8DPP9TSHR | |
| SCHEMBL2254925 | 0.79 | CRHR1 (0.48) | PLATCRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011529943-A | — | — | 2011-12-15 | — | — | JP | claimed |
| US-7994203-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-08-09 | — | — | US | claimed |
| EP-2328902-A1 | PYRAZOLO [5,1-B]OXAZOLE DERIVATIVES AS CRF1 ANTAGONISTS | Novartis AG (CH) | 2011-06-08 | — | — | EP | claimed |
| WO-2010015628-A1 | PYRAZOLO [5,1-B] OXAZOLE DERIVATIVES AS CRF1 ANTAGONISTS | NOVARTIS AG (CH) | 2010-02-11 | — | — | WO | claimed |
| US-20100035874-A1 | Organic compounds | NOVARTIS AG (CH) | 2010-02-11 | — | — | US | claimed |
| US-7994203-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-08-09 | — | — | US | disclosed |
| US-7994203-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-08-09 | — | — | US | disclosed |
| US-7994203-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-08-09 | — | — | US | disclosed |
| US-20100035874-A1 | Organic compounds | NOVARTIS AG (CH) | 2010-02-11 | — | — | US | disclosed |
| US-20100035874-A1 | Organic compounds | NOVARTIS AG (CH) | 2010-02-11 | — | — | US | disclosed |
| US-20100035874-A1 | Organic compounds | NOVARTIS AG (CH) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035874-A1 | Organic compounds | CRH, CRHR1, CRHR2 | PLAT 3787/4885GPBAR1 307/4885DPP4 958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.